Core trends in 2023 FDA drug approvals: Oncology, neurology and hematology dominate

2023 was a big year for hematology, neurology and oncology, with the medical specialties seeing the most FDA approvals. In terms of sponsors, Pfizer had the most approvals with six total, followed by UCB and Chiesi, each with three apiece.

When looking at commercial prospects, AstraZeneca’s respiratory syncytial virus antibody Beyfortus could be the biggest blockbuster from the 2023 cohort with expected peak sales of $1.9 billion. Alzheimer’s drug Leqembi could also be a major success, making up for the tepid demand for Aduhelm, which won conditional approval in 2021. While Aduhelm’s sales have sputtered, Leqembi could see peak revenue of $4.8 billion according to analysts.

Oncology continues to be a hot specialty with the most competition among the newly approved drugs, as the FDA continues to green light new entrants in crowded target classes such as PD-1 inhibitors.

google.charts.load('current', { 'p…
Read more
  • 0

How Siemens will accelerate adoption of Scopio’s AI-powered telehematology tech

Scopio’s partnership with Siemens Healthineers will “accelerate digital workflow transformation in hematology laboratories worldwide,” Scopio CEO Itai Hayut said. [Photo courtesy of Siemens Healthineers]

Scopio Labs has enlisted a huge partner to get its telehematology technology into more labs.

Scopio and Siemens Healthineers today announced a global distribution deal for the Scopio X100 and Scopio X100HT.

Siemens said those full-field digital cell morphology technology systems will complement its own Atellica HEMA 570 and Atellica HEMA 580 analyzers to give labs “high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network.”

Siemens Healthineers Head of Diagnostics Sharon Bracken called the deal “a step forward in delivering automated and…

Read more
  • 0